At Keystone Nano, we tackle huge challenges at the nano level. We’re developing nanoscale solutions for better treatment of cancer and for improvements in difficult-to-solve industrial chemistries. We have both an internal development program and a series of co-development programs with partner companies, using our unique nanoparticles to deliver their actives. • NanoJackets. Keystone Nano has an exclusive license to technology patented by Penn State University that allows the creation of stable, non-toxic, long-lasting 5 to 50 nm-composite particles that we call NanoJackets. Composed principally of calcium phosphosilicates, these NanoJackets can encapsulate drugs or fluorescent molecules. Unlike most other nanoparticles, NanoJackets have biocompatible base materials, dissolve upon entering cells, and can be passively or actively targeted. • Nanoliposomes. Our technology allows the creation of small liposomes with well-defined size, charge, and stability that have demonstrated effectiveness against melanoma, breast cancer, and leukemia. Nanoliposomes can carry ceramide and other compounds of interest. We can scale up liposomes and conduct a range of physical and biological characterizations. We invite you to partner with us to accelerate the commercialization of new products that use nanotechnology to improve the treatment of disease and the quality of life.